Literature DB >> 26586722

Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.

Jennifer Chu1, Regina Cencic1, Wenyu Wang2, John A Porco2, Jerry Pelletier3.   

Abstract

Rocaglates are natural products that inhibit protein synthesis in eukaryotes and exhibit antineoplastic activity. In vitro biochemical assays, affinity chromatography experiments coupled with mass spectrometry analysis, and in vivo genetic screens have identified eukaryotic initiation factor (eIF) 4A as a direct molecular target of rocaglates. eIF4A is the RNA helicase subunit of eIF4F, a complex that mediates cap-dependent ribosome recruitment to mRNA templates. The eIF4F complex has been implicated in tumor initiation and maintenance through elevated levels or increased phosphorylation status of its cap-binding subunit, eIF4E, thus furthering the interest toward developing rocaglates as antineoplastic agents. Recent experiments have indicated that rocaglates also interact with prohibitins 1 and 2, proteins implicated in c-Raf-MEK-ERK signaling. Because increased ERK signaling stimulates eIF4E phosphorylation status, rocaglates are also expected to inhibit eIF4E phosphorylation status, a point that has not been thoroughly investigated. It is currently unknown whether the effects on translation observed with rocaglates are solely through eIF4A inhibition or also a feature of blocking eIF4E phosphorylation. Here, we show that rocaglates inhibit translation through an eIF4E phosphorylation-independent mechanism. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26586722      PMCID: PMC4707080          DOI: 10.1158/1535-7163.MCT-15-0409

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  34 in total

1.  Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.

Authors:  Christina M Rodrigo; Regina Cencic; Stéphane P Roche; Jerry Pelletier; John A Porco
Journal:  J Med Chem       Date:  2011-12-19       Impact factor: 7.446

2.  eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.

Authors:  Luc Furic; Liwei Rong; Ola Larsson; Ismaël Hervé Koumakpayi; Kaori Yoshida; Andrea Brueschke; Emmanuel Petroulakis; Nathaniel Robichaud; Michael Pollak; Louis A Gaboury; Pier Paolo Pandolfi; Fred Saad; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

3.  Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities.

Authors:  Ivan Topisirovic; Melisa Ruiz-Gutierrez; Katherine L B Borden
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

Review 4.  Targeting the eIF4A RNA helicase as an anti-neoplastic approach.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Biochim Biophys Acta       Date:  2014-09-16

5.  Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies.

Authors:  C Tschopp; U Knauf; M Brauchle; M Zurini; P Ramage; D Glueck; L New; J Han; H Gram
Journal:  Mol Cell Biol Res Commun       Date:  2000-04

6.  Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.

Authors:  Takeshi Ueda; Rie Watanabe-Fukunaga; Hidehiro Fukuyama; Shigekazu Nagata; Rikiro Fukunaga
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

7.  Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.

Authors:  Heather Sadlish; Gabriela Galicia-Vazquez; C Gregory Paris; Thomas Aust; Bhupinder Bhullar; Lena Chang; Stephen B Helliwell; Dominic Hoepfner; Britta Knapp; Ralph Riedl; Silvio Roggo; Sven Schuierer; Christian Studer; John A Porco; Jerry Pelletier; N Rao Movva
Journal:  ACS Chem Biol       Date:  2013-05-07       Impact factor: 5.100

8.  Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Authors:  Francis Robert; William Roman; Alexandre Bramoullé; Christof Fellmann; Anne Roulston; Chaim Shustik; John A Porco; Gordon C Shore; Michael Sebag; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

9.  Dissecting eIF4E action in tumorigenesis.

Authors:  Hans-Guido Wendel; Ricardo L A Silva; Abba Malina; John R Mills; Hong Zhu; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Julie Teruya-Feldstein; Jerry Pelletier; Scott W Lowe
Journal:  Genes Dev       Date:  2007-11-30       Impact factor: 11.361

10.  Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Authors:  Houda Alachkar; Ramasamy Santhanam; Jason G Harb; David M Lucas; Joshua J Oaks; Christopher J Hickey; Li Pan; A Douglas Kinghorn; Michael A Caligiuri; Danilo Perrotti; John C Byrd; Ramiro Garzon; Michael R Grever; Guido Marcucci
Journal:  J Hematol Oncol       Date:  2013-03-16       Impact factor: 17.388

View more
  14 in total

1.  Total Syntheses of the Isomeric Aglain Natural Products Foveoglin A and Perviridisin B: Selective Excited-State Intramolecular Proton-Transfer Photocycloaddition.

Authors:  Wenyu Wang; Anthony Clay; Retheesh Krishnan; Neil J Lajkiewicz; Lauren E Brown; Jayaraman Sivaguru; John A Porco
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-13       Impact factor: 15.336

2.  Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Authors:  Salomon Manier; Daisy Huynh; Yu J Shen; Jia Zhou; Timur Yusufzai; Karma Z Salem; Richard Y Ebright; Jiantao Shi; Jihye Park; Siobhan V Glavey; William G Devine; Chia-Jen Liu; Xavier Leleu; Bruno Quesnel; Catherine Roche-Lestienne; John K Snyder; Lauren E Brown; Nathanael Gray; James Bradner; Luke Whitesell; John A Porco; Irene M Ghobrial
Journal:  Sci Transl Med       Date:  2017-05-10       Impact factor: 17.956

3.  METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.

Authors:  Shuo Liu; Simone Hausmann; Scott Moore Carlson; Mary Esmeralda Fuentes; Joel William Francis; Renjitha Pillai; Shane Michael Lofgren; Laura Hulea; Kristofferson Tandoc; Jiuwei Lu; Ami Li; Nicholas Dang Nguyen; Marcello Caporicci; Michael Paul Kim; Anirban Maitra; Huamin Wang; Ignacio Ivan Wistuba; John Anthony Porco; Michael Cory Bassik; Joshua Eric Elias; Jikui Song; Ivan Topisirovic; Capucine Van Rechem; Pawel Karol Mazur; Or Gozani
Journal:  Cell       Date:  2019-01-03       Impact factor: 41.582

4.  eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.

Authors:  Tim Kong; Yibo Xue; Regina Cencic; Xianbing Zhu; Anie Monast; Zheng Fu; Virginie Pilon; Veena Sangwan; Marie-Christine Guiot; William D Foulkes; John A Porco; Morag Park; Jerry Pelletier; Sidong Huang
Journal:  Mol Cancer Ther       Date:  2019-08-08       Impact factor: 6.261

5.  Intercepted Retro-Nazarov Reaction: Syntheses of Amidino-Rocaglate Derivatives and Their Biological Evaluation as eIF4A Inhibitors.

Authors:  Wenhan Zhang; Jennifer Chu; Andrew M Cyr; Han Yueh; Lauren E Brown; Tony T Wang; Jerry Pelletier; John A Porco
Journal:  J Am Chem Soc       Date:  2019-07-30       Impact factor: 15.419

6.  Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.

Authors:  Stacey L Lehman; Theresa Wechsler; Kayla Schwartz; Lauren E Brown; John A Porco; William G Devine; Jerry Pelletier; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

7.  Synthesis of Aza-Rocaglates via ESIPT-Mediated (3+2) Photocycloaddition.

Authors:  Wenyu Wang; Regina Cencic; Luke Whitesell; Jerry Pelletier; John A Porco
Journal:  Chemistry       Date:  2016-07-15       Impact factor: 5.236

8.  Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection.

Authors:  Wenhan Zhang; Shufeng Liu; Rayelle I Maiga; Jerry Pelletier; Lauren E Brown; Tony T Wang; John A Porco
Journal:  J Am Chem Soc       Date:  2019-01-11       Impact factor: 15.419

Review 9.  Targeting RNA helicases in cancer: The translation trap.

Authors:  Marise R Heerma van Voss; Paul J van Diest; Venu Raman
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-09-28       Impact factor: 10.680

10.  nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs.

Authors:  Valentina Gandin; Laia Masvidal; Laura Hulea; Simon-Pierre Gravel; Marie Cargnello; Shannon McLaughlan; Yutian Cai; Preetika Balanathan; Masahiro Morita; Arjuna Rajakumar; Luc Furic; Michael Pollak; John A Porco; Julie St-Pierre; Jerry Pelletier; Ola Larsson; Ivan Topisirovic
Journal:  Genome Res       Date:  2016-03-16       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.